Introduction
Angiogenesis is a key mechanism in the pathogenesis of numerous diseases such as cancer, atherosclerosis, and eye diseases (Carmeliet, 2005) . Inflammation can be a potent trigger of angiogenesis (Shaik-Dasthagirisaheb et al., 2013) , especially in ocular conditions such as exudative macular degeneration, uveitis and infectious keratitis (Chang et al., 2001; Winterhalter et al., 2012) . In the cornea, angiogenesis (or corneal neovascularization) has traditionally been treated with topical steroids in the active phase, whereas in a later phase only surgical procedures with often poor prognosis, if any therapy at all, are possible (Chang et al., 2001; Shakiba et al., 2009) . Steroids are known from clinical practice to be effective, nevertheless they can also have frequent and serious side effects, including secondary glaucoma, corneal thinning and perforation, cataract, and herpes infection (Fel et al., 2012; Shakiba et al., 2009; ) . In recent years, anti-Vascular Endothelial Growth Factor treatment (anti-VEGF) has become first-line therapy in choroidal neovascularization (exudative maculopathy) (Kovach et al., 2012) , and is also used to treat corneal neovascularization (offlabel) (Chang et al., 2012; Hosseini et al., 2012) . While this more targeted treatment avoids the side-effects of steroids, experimental and clinical studies have shown only a limited reduction in corneal neovessels. Using locally-applied anti-VEGF by topical (Dastjerdi et al., 2009) , subconjunctival (Petsoglou et al., 2013) , intrastromal (Vieira et al., 2012) , or intraocular (Avisar et al., 2010) route), neovessel reduction in the range of 15-20 % in experimental studies (Rocher et al., 2011) , and of 36-61% in clinical studies (Dastjerdi et al., 2009; König et al. 2009; Petsoglou et al. 2013 ) has been reported. Anti-VEGF may also have a shorter therapeutical window compared to steroids (Nakao et al., 2012) . The reason for this limited and variable efficacy, however, remains unclear.
In the context of inflammation, damage to the corneal tissue can be inflicted before visible signs of vessel ingrowth. For example, stromal invasion of leukocytes (Bourghardt Peebo et al., 2007; Fagerholm and Gan, 2001; Gong and Koh, 2010; Nakao et al., 2012) which produce pro-angiogenic cytokines, precede and promote vessel invasion, and at a later stage could reactivate vessel growth upon cessation of treatment (Cursiefen et al., 2004; Gong and Koh, 2010; Lu et al., 2012; Sakurai et al., 2003; Sunderkötter et al., 1994; Tazzyman et al., 2013) . Besides this paracrine function, evidence is mounting that inflammatory cells may have a more direct role in tissue remodeling and the formation of new vessels (Bourghardt Peebo et al., 2011; Fantin et al., 2010; Kim et al., 2009; Maruyama et al., 2005) .
This early inflammation and damage is often invisible upon clinical examination. Current methods to assess the efficacy of anti-angiogenic treatments have overwhelmingly focused on examination with slit lamp and photography (Chen et al., 2009; Cheng et al., 2012; Chung and Lee, 2012; Dastjerdi et al., 2009; Yoeruek et al., 2008) , partly due to the lack of specific methods to detect early inflammation and tissue damage in corneal neovascularization. We have previously showed that it is possible to detect early signs of inflammation by in vivo confocal microscopy (IVCM) (Peebo et al., 2010) . A more complete assessment of antiangiogenic therapy would therefore include quantification of its suppressive effect on the dynamics of tissue inflammation at both the tissue and pathway level. Moreover, by investigating specific differences between anti-VEGF and steroid treatment, factors could be identified that may eventually combine the efficacy of dexamethasone with the higher specificity and lower side effects of anti-VEGF therapy.
The aim of this study was therefore to focus on the early phases of angiogenesis (presprouting and immediately post-sprouting) to investigate whether dexamethasone and anti-VEGF treatments differentially influenced cells, tissue, vessels, and the gene expression of several major angiogenic and inflammatory pathways.
Materials & Methods

2.1.Suture-induced rat inflammatory corneal neovascularization assay:
55 twelve-to sixteen-week-old male Wistar rats weighing 300 to 400g (Scanbur AB, Sollentuna, Sweden) were used. All animals were treated following the Association for Research in Vision and Ophthalmology (ARVO) guidelines for the Use of Animals in Ophthalmic and Vision Research. With approval from the Linköping regional animal ethics review board, (application no. 7-13), rats were anesthetized using intraperitoneal injection of dexmeditomedine (Orion Pharma AB, Sollentuna, Sweden) and xylazine (Pfizer AB, Sollentuna, Sweden). After topical administration of 1% tetracaine (Chauvin Pharmaceuticals Ltd, London, England), a corneal stromal suture (10-0 nylon) was placed 1.5 mm from the temporal limbus as previously described (Bourghardt Peebo et al., 2011) . The time of suture placement was considered to be t = 0. Left eyes were left untouched in sutured rats, and three rats were left un-sutured to provide negative control samples for Real Time Polymerase Chain Reaction (RT-PCR).
Treatments
After suturing the cornea, rats (n= 52) were randomly assigned to three groups where all animals received topical instillation of eye drops in the right eye four times daily for 7 days. Treatment groups were as follows: a) Anti-VEGF (n=18). A neutralizing rat specific goat polyclonal pan-VEGFA antibody (Cat. No AF 564, R&D Systems, Minneaplois MN) was used, rather than the humanized monoclonal antibody bevacizumab, to enhance speciesspecific sensitivity. The antibody was diluted aseptically by PBS (PBS-A, APL, Kungens Kurva, Sweden) at a dose of 10µg/ml. b) Steroids (n=20): The preservative-free dexamethasone 0.1 % (Opnol, Clean Chemical Sweden AB, Borlänge, Sweden) was used. c) Control (n=14): Control rats received normal goat IgG antibody (Cat. No. 108-C, R&D Systems), diluted aseptically by PBS at a dose of 10µg/ml. The untouched group (n=3) did not receive any treatment.
At either 24 h, day 2, or day 7, animals were euthanized by intracardial injection of 100 mg/kg pentobarbital sodium (Apoteket AB, Linköping, Sweden) while under deep anaesthesia. The entire cornea without scleral rim was then excised and the temporal portion was prepared and immediately frozen to -70°C for immunohistochemistry or to -20°C for RT-PCR. Six corneas from three untouched rats were used for RT-PCR as negative controls.
In vivo confocal microscopy
In this study we used laser scanning in vivo confocal microscopy (IVCM), with an instrument clinically approved for use in imaging the eye (Heidelberg Retinal Tomograph 3 with Rostock Corneal Module, Heidelberg Engineering). The microscope was equipped with a 63x/0.95 NA water-immersion objective (Zeiss, Oberkochen, Germany) , that provides an en face view of a 400 µm x 400 µm corneal area at a selectable corneal depth. The IVCM imaging technique has been described in detail elsewhere (Bourghardt Peebo et al., 2011; Peebo et al., 2011 Peebo et al., ,2010 . The focal depth of the HRT3 was initially adjusted to image the corneal epithelial surface, and the lateral and transverse microscope alignments were adjusted to locate the suture in the real-time image display window. Once the suture was located, the focal plane was adjusted axially to locate inflammatory cells, limbal blood vessels, or stromally-located angiogenic vessels. Typically, these structures of interest were confined to a thin subepithelial stromal region from 0-40µm below the basal epithelium. Digital images were recorded at 5 frames/s while lateral, transverse, and axial controls were adjusted during image capture to locate and follow the path of cells or vessels from the limbus to the suture area. IVCM has been shown to be a valuable tool for imaging of various cells in transparent tissue, noninvasively, in a time-lapse manner, without the need for cell labeling (Bourghardt Peebo et al., 2011; Peebo et al., 2011 Peebo et al., ,2010 .
Five animals from each treatment group were randomly chosen for in vivo follow up with IVCM. At 5h, days 2 and 7, animals were anesthetized, eyes were photographed in the operating microscope, and IVCM was performed. Once the suture was located, the microscope field of view (400µm × 400 µm) was translated temporally to locate the limbal region. A typical examination consisted of 10 image sequences with each sequence containing 100 successive digital image frames.
Inflammatory cell migration from limbus into the corneal stroma was analyzed from selected representative images. Image measurements were then performed using Image J (ImageJ software, developed by Wayne Rasband, National Institutes of Health, Bethesda, MD; available at http://rsb.info.nih.gov/ij/index.html). To enhance assay reproducibility, images with clear inflammatory cell infiltration from the same corneal depth (depth where limbal vessels were in focus) were chosen. All images were coded to mask the observer to the treatment group of a given eye. For evaluation of cell migration at 5h, the distance between the limbal arcade and the most distal leading inflammatory cells in the corneal stroma was measured with Neuron J linear alignment tool (Meijering et al., 2004) . This distance value was used in statistical analysis.
To quantify inflammatory cell infiltration at days 2 and 7, three distinct coded IVCM images per sutured cornea were first selected from the stromal region between the limbus and suture (no limbus or suture visible). Next, each image was pre-processed in ImageJ by applying the following built-in ImageJ functions: background subtraction, sharpening, noise reduction, thresholding to exclude the brightest 5% of pixels, conversion to binary, and the watershed function to separate adjoined cells. After pre-processing, cells in the binary images were automatically counted using the built-in 'analyze particles' function in ImageJ. All separate regions larger than 36 square pixels were deemed as inflammatory cells and were included in the automatic cell count. The automatic count was performed twice (to include and exclude cells on image borders), and the two counts were averaged. Cell counts per frame were then used in the statistical analysis.
Limbal vessel expansion in response to the different treatments was quantified on IVCM images of the limbal arcade at 5h and day 2. Images with distinct vessels with blood flow were selected, and were in-focus and generally at the same corneal depth. Blood vessels had a constant diameter and were measured once per vessel or twice in a loop (once in each connecting vessel) using ImageJ.
Mature macrophages were first identified by immunofluorescent staining. They had a characteristic in vivo morphologic appearance and preferentially accumulated at the suture site. IVCM images of the suture site at days 2 and 7 were then selected from the treated corneas, based on the criteria of the presence of at least one mature macrophage in the image. Up to 3 images depicting distinct areas with mature macrophages were chosen from each cornea. Macrophages were then manually counted using the 'Cell Counter' plugin to ImageJ, and counts were recorded for statistical analysis.
In vivo photographic vessel analysis
Photographs from the operating microscope from 25 sutured rats at day 7 were used to measure total vessel length and vessel invasion area. Using ImageJ software, color photographs were first digitally converted to red free images, then inverted and sharpened. NeuronJ was then used to trace the path of visible blood vessels in a semi-automated manner ( Figure 1 ). Total vessel length was defined as the total length (in mm) of all traced vessels in a given cornea, while vessel invasion area was defined by the area of the polygon with verticies given by the furthest invading vessel tips in the cornea and by the limbal border. The ImageJ line and area calculator tools were used for quantification. Vessels were traced and invasion area was measured by two independent observers, and the average value of the two observers was taken.
Immunohistochemistry
Frozen corneas were thawed and rinsed in PBS; fixed in acetone; rinsed in PBS 3 times; blocked in 10 % normal donkey serum (Jackson ImmunoResearch Europe, Newmarket, UK) and incubated with primary antibodies overnight. The next day, samples were rinsed, blocked, and incubated with secondary antibodies overnight. For double immunostaining, this procedure was repeated. The primary antibodies used were: pan-endothelial marker CD31/PECAM-1 (Santa Cruz Biotechnology Inc. Santa Cruz, CA, USA), myeloid lineage marker CD11b (Santa Cruz), and a marker for mature rat macrophages KiM2R (Abcam PLC , Cambridge, UK). Secondary antibodies (Jackson) included Dylight 549 and Dylight 488. All imaging was performed using a laser-scanning confocal fluorescence microscope (Nikon Eclipse E600 or Zeiss LSM 700) equipped with 40x/1.30 NA oil-immersion or 20x/0.75 NA objective lenses. Samples were scanned under single or dual laser excitation and a digital camera was used to record images. In all cases, control samples were used and omission of the primary antibody eliminated cell-specific staining.
2.6. Real-time quantitative RT-PCR 42 corneas were harvested for reverse transcriptase polymerase chain reaction (RT-PCR) analysis: 6 corneas from 3 untouched rats as negative control samples, and 12 corneas from each treatment group. 9 corneas per treatment group were excised 24h after placing the suture, and 3 per treatment group were excised at day 7.
Total RNA from each corneal sample was isolated with RNeasy Mini Kit (Qiagen). RNA concentrations were determined using a Nanodrop ND-2000 spectrophotometer (Nanodrop Technologies), and the complementary DNA (cDNA) was synthesized from the total RNA (100 ng) using a SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen) in accordance with the manufacturer's instructions. PCR reactions were performed on all corneal samples (nonpooled) using TaqMan The Ct values for samples were determined, and relative target gene mRNA expression was calculated by the Ct method, using β-actin (Cat. No. Rn00667869_m1) and Glyceraldehyde Phosphate Dehydrogenase (GAPDH, Cat. No. Rn01775763_g1) as endogenous housekeeping control genes. Gene expression level was reported relative to the average relative expression level in the negative control samples. All reactions were carried out using an ABI PRISM 7900HT Real-Time PCR system (Applied Biosystems) and were repeated in triplicate.
2.7.Statistical analysis
Statistical comparison of blood vessel lumen diameter, total vessel length, vessel invasion area, inflammatory cell migration at 5h, inflammatory cell presence at day 2 and 7, macrophage presence at day 2 and 7, and gene expression across groups was performed using one-way analysis of variance (ANOVA). Normality in the distribution of data was determined by the Kolmogorov-Smirnov test. Where data was normally-distributed, the one-way ANOVA was used with multiple pairwise comparisons performed by the Student-NewmanKeuls method. For non-normally distributed data, the Kruskal-Wallis one-way ANOVA on ranks was used, with pairwise multiple comparisons performed using Dunn's Method. All comparisons were performed using statistical software (SigmaStat, Syastat Software Inc. Chicago, IL, USA) and a two-tailed value of p < 0.05 was considered statistically significant.
Results
3.1.Early migration of myeloid cells is delayed by anti-VEGFA and dexamethasone treatment.
Early migrating inflammatory cells were observed to enter the cornea en masse (Bourghardt Peebo et al., 2011; Li et al., 2006) with a clear wavefront between invaded and un-invaded corneal stroma (Figure 2A ). Treatment with dexamethasone and anti-VEGF significantly slowed the migration of these CD11b+ myeloid cells at 5h in comparison to controls (P = 0.03; Figure 2B , C), but no difference was noted between anti-VEGF and dexamethasone treatment.
By day 2, the corneal stroma from the limbus to the suture site was densely infiltrated by myeloid cells in all groups. Cell quantification revealed a diminished number of myeloid cells in the anti-VEGF group in comparison to the dexamethasone group (P = 0.03), but more stromal edema was present in anti-VEGF treated corneas, compared to the dexamethasone group, ( Figure 3A ) making visualization of inflammatory cells more difficult . This difference did not persist to day 7, where myeloid cell counts did not differ between treatment groups (P = 0.34), although the number of cells at day 7 was slightly reduced in all groups compared to day 2. (Figure 3 ).
Sustained suppression of early limbal vessel dilation by dexamethasone.
In vivo measurement of vessel dilation revealed that early-phase limbal vessel dilation at 5h was inhibited in both treatment groups in comparison to controls (P < 0.001; Figure 4A ). By day 2, dexamethasone-treated corneas continued to significantly inhibit dilation relative to controls (P < 0.001) while anti-VEGF treatment did not (P > 0.05; Figure 4 ). Measurements of limbal vessel diameter at day 7 could not be performed since corneas in anti-VEGF treated and control groups were vascularized and hence, original limbal vessels were no longer identifiable in vivo.
Early macrophage recruitment is suppressed by dexamethasone.
The in vivo morphology of macrophages is known from an earlier study and was in addition confirmed by ex vivo whole mount immunostaining with the mature macrophage marker Ki-M2R ( Figure 5 ). Mature macrophages were observed in vivo to accumulate at the suture site. Macrophage quantification at the suture site revealed that dexamethasone treatment significantly reduced the recruitment of macrophages at day 2 in comparison to anti-VEGF treatment and controls (P = 0.027). By day 7, the number of macrophages had increased in all groups, but the total number of macrophages in anti-VEGF and dexamethasone-treated corneas was still significantly reduced in comparison to controls (P = 0.001; Figure 5 ). Macrophages in the dexamethasone-treated group were reduced relative to the anti-VEGF group at day 7, but this difference did not reach statistical significance (P = 0.33).
Effect of topical dexamethasone and anti-VEGF treatment on corneal neovascularization
Photographic analysis in vivo revealed that dexamethasone treatment significantly suppressed corneal neovascularization at day 7 ( Figure 6 ). In comparison to controls, total vessel length was reduced by 95.3% and vessel invasion area by 93.1% (P < 0.001 for both measures, relative to both anti-VEGF and controls). The inhibitory effect of anti-VEGF was significantly weaker than dexamethasone (P < 0.05) with a reduction of vessel length by 14.4% and invasion area by 13.8% relative to controls at day 7 (P > 0.05 for both measures; Figure 6 ).
Modulation of inflammatory and angiogenic gene expression by treatment
To assess the effect of treatments on the gene expression of several key inflammatory and angiogenic mediators, but also to verify efficacy of topical drug delivery, RT-PCR was performed at day 7 for VEGFA, FGF-2, IL-6, CXCL2, CCL2, CCL3 and TNF-α, in the same corneas examined longitudinally by IVCM. The factors chosen represent major and well known angiogenic, inflammatory, and macrophage-related factors. In sutured corneas, expression of all cytokines was significantly up-regulated relative to non-sutured negative control corneas (P < 0.001; Figure 7B ), except for FGF2 which was slightly down-regulated (P > 0.05). In both dexamethasone and anti-VEGF groups, the expression of VEGFA, IL-6 and CCL2 was significantly down-regulated (P < 0.05) compared to control IgG treatment. There was no significant difference, however, between dexamethasone and anti-VEGF groups in gene expression for these three factors (P > 0.05). Expression of TNF-α, CXCL2, and CCL3 did not differ between groups.
Due our observation of a large difference in corneal neovascularization between treatments despite similar gene expression at day 7, we decided to investigate gene expression earlier in the pre-sprouting, inflammatory phase. Delta-like ligand 4 (DLL4) was additionally included, due to its regulation of early sprouting of neovessels (Suchting et al., 2007) . RT-PCR was therefore performed using corneal tissue samples extracted at 24 h for VEGF-A, FGF-2, IL-6, TNF-α, CXCL2, CCL2, CCL3, and DLL4 ( Figure 7A ). VEGF-A, FGF-2, IL-6, and TNF-α were all significantly down-regulated in both treatment groups relative to controls, with no significant difference between anti-VEGF and dexamethasone groups for these genes. Expression of CXCL2, CCL2, CCL3, and DLL4 did not differ between the groups at 24h.
In summary, VEGFA and IL-6 were strongly down-regulated by both dexamethasone and anti-VEGF in the early pre-sprouting phase (at 24 h), and this inhibition continued to day 7. Even FGF-2 and TNF-α were down-regulated at 24 h by both treatments. No significant down-regulation of CCL2 expression could be detected at 24 h, but this down-regulation became evident by day 7. No modification of the expression of CCL 3 and CXCL2 could be detected at either 24h or at day 7.
Discussion
In this study, in vivo longitudinal examination of the same corneas revealed that antiangiogenic treatments can influence early, pre-angiogenic tissue activity such as limbal vessel dilation, inflammatory cell infiltration of the stroma, and macrophage accumulation. Importantly, this early activity was perturbed by both dexamethasone and anti-VEGF treatment within the first two days after suturing, before the first angiogenic sprouts typically appear at the limbus in our model (Bourghardt Peebo et al., 2011) .
Clearly both anti-VEGF and dexamethasone suppress numerous cytokines, results that also confirmed drug penetration in our topical treatment model. Generally, the penetration of topically instilled dexamethasone into the cornea is known from clinical experience and earlier experimental studies (Bessonova et al., 2011; Hoffart et al., 2010; Hos et al., 2011) . Topical anti-VEGF antibodies have similarly shown good penetration into the cornea, particularly after local disruption of the epithelial barrier and induction of inflammation and angiogenesis (Rocher et al., 2011; Stevenson et al., 2012; Yoeruek et al., 2008) . In the present study, RT-PCR also revealed a significant effect on many cytokines belonging to inflammatory and angiogenic pathways as early as 24h, indicating the rapid effect of the topical treatments.
Differences in vessel dilation and inflammatory cell migration between treatment groups were visible as early as 5h after suturing. While both dexamethasone and anti-VEGF treatment delayed cell migration and vessel dilation at this early phase, these effects had subsided in the anti-VEGF group by day 2. At day 2, in dexamethasone-treated corneas, limbal vessels continued to resist dilation, and accumulation of mature macrophages at the suture site was suppressed despite an increased number of infiltrating myeloid cells (macrophages likely collect at the suture in an attempt to digest foreign material (van Putten et al., 2013) , but even play a role in producing VEGF and other cytokines (Lu et al., 2008) . Interestingly, these two parameters in the pre-sprouting phase at day 2 appeared to correlate with final neovascular invasion at day 7, while the early migration of inflammatory myeloid cells and total myeloid cell presence did not appear to relate to the final development of neovessels. The inhibitory effect of steroids and anti-VEGF treatment on early cell invasion is in accordance with earlier reports demonstrating delayed migration of inflammatory cells in an ex vivo setting (Hos et al., 2011; Nakao et al., 2012 Nakao et al., , 2007 Oh et al., 2009) . Little is known, however, about the effect of anti-angiogenic treatments on the dynamics of microvascular dilation, a process which is an important step in the early angiogenic process. Steroids have been shown to have an inhibitory effect on vessel caliber in a chorioallantoic membrane model (McKay et al., 2008) and in a clinical study in patients with diabetic macular edema (Wickremasinghe et al., 2008) , indicating an inhibitory effect of steroids on inflammatory cytokines inducing vessel expansion. The ability of anti-VEGF treatment to reduce mature vessel caliber has been demonstrated after topical instillation of bevacizumab in clinical studies König et al., 2009; Stevenson et al., 2012) , an effect likely arising from blocking the permeability properties of VEGF.
One surprising finding revealed by the in vivo analysis was the dense infiltration of inflammatory myeloid cells in dexamethasone-treated corneas that persisted from day 2 through 7. Despite the absence of blood vessels in these corneas, inflammatory cells were abundant. A similar infiltration of neutrophils into the cornea following steroid treatment has been shown in earlier studies in corneal tissue (Nakao et al., 2012 (Nakao et al., , 2007 , while another study implicated glucocorticoids in the recruitment of specific anti-inflammatory leukocyte subsets . Moreover, in the resolution phase of inflammation, glucocorticoids have been shown to facilitate apoptosis of eosinophils, but undesirably prolong neutrophil survival (Cox 1995) . Technical artifacts such as better visualization of inflammatory cells in corneas with less stromal edema (dexamethasone group), or the limitations of a two-dimensional analysis of inflammatory cells present at various depth layers in the cornea may have impacted the results. Further investigation of the inflammatory cells, their associated cytokines, and their pro-or anti-angiogenic role in the current model is warranted.
Anti-VEGF treatment did not appear to suppress myeloid cell recruitment at day 2 and 7 in our model in contrast to other rat models of corneal injury, where inflammatory cells were significantly suppressed by subconjunctival administration of bevacizumab (Oh et al., 2009; Sener et al., 2011) but not ranibizumab (Sener et al., 2011) . Conflicting results may be due to different models, species-dependent effects (we used rat-specific anti-VEGF), quantification techniques, and drug delivery methods. The longitudinal in vivo analysis, however, could shed light on dynamic changes in inflammation whereas fixed tissue specimens only provide the status of inflammation at a specific time point.
In the present study, dexamethasone suppressed corneal neovascularization by over 90%. Suppression of corneal neovasularization by 57-75 % with dexamethasone has been reported previously in rodent models (Hoffart et al., 2010; Hos et al., 2011; Nakao et al., 2012 Nakao et al., , 2007 . Anti-VEGFA treatments, however, have had a comparatively poorer efficacy in both animal and clinical studies (Bahar et al., 2008; Hoffart et al., 2010; Farid and Zaki, 2010) , with some studies noting only borderline reduction in neovascular area (Oh et al., 2009 ) while others report greater reduction in invasion area relative to controls (Bock et al., 2007; DratvimanStorobinsjy et al., 2009; Manzano et al., 2007) . In this study, a reduction of 14% in invasion area relative to sham-treated controls did not reach significance. This result may indicate limited effectiveness of the anti-VEGF treatment (Dastjerdi et al., 2009 ), but may also partly reflect the small vascularized area of the rat cornea in our temporal suture model. The model, designed for longitudinal in vivo examination, induces vessels in a well-defined region of the cornea between the limbus and the suture, limited to about one-tenth of the cornea's total surface area. In other animal models with several central sutures (Bock et al. 2007; Cursiefen et al., 2004; Hos et al., 2011) or a large-area alkali burn (Dratviman-Storobinsky et al., 2009; Gong and Koh, 2010; Hoffart et al., 2010; Sener et al., 2011 ) a large region of the cornea can become vascularized, which allows for greater sensitivity in detecting significant reductions in invasion area, but a less predictable and controlled pattern of vascularization.
Our in vivo findings led us to investigate whether the topical anti-angiogenic treatments, while in general not successful in inhibiting myeloid cell recruitment to the cornea, may effectively block their pro-angiogenic cytokine release (Gong and Koh, 2010; Sunderkötter et al., 1994; Tazzyman et al., 2013) . Interestingly, Zakaria et al. (2012) have shown from studies of human tears that inflammatory cytokines such as IL-6, IL-8 are positively correlated with the presence of corneal neovascularization. Inhibition of early recruitment or maturation of macrophages by anti-angiogenic agents may also play an important role in later corneal neovascularization (Cursiefen et al., 2004; Lu et al., 2012; Sakurai et al., 2003; Sunderkötter et al., 1994) . As expected, VEGF-A expression was suppressed in the treatment groups, alongside with IL-6, a widespread inflammatory cytokine that has been shown to have bidirectional associations with VEGF-A (Tartour et al., 2011; Zakaria et al 2012) . This effect was already detected in the early phase (24 h) and persisted until day 7. Several studies in different models of corneal inflammation have found a significantly reduced expression of IL-6 after treatment with bevacizumab (Chung and Kang, 2010; Oh et al., 2009) , demonstrating the close relation between VEGF and IL-6 in inflammation. A further interesting finding in this study was the ability of anti-VEGF treatment to down-regulate FGF-2 at 24 h, to an equal degree as dexamethasone, given that the FGF family is considered to represent aVEGFindependent pathway. This suppression did, however not persist to day 7. Another potent inflammatory cytokine, TNF-α, was significantly down-regulated by both treatments in the early phase, but this effect was not detectable at day 7. CCL2, also called monocyte chemotactic protein-1 (MCP-1) has been shown to promote recruitment of monocytes, memory T-cells, and dendritic cells to the inflammation site (Goede et al. 1999; Ueno et al., 2000) . Its expression did not appear to be modified by treatment at 24h, but its downregulation at day 7 in treated corneas paralleled the reduced presence of mature macrophages at the same time point. Despite this reduction in macrophage recruitment, however, neovascularization was still abundant in the anti-VEGF group, indicating a complexity of macrophage activity and the possible contribution of unidentified pro-angiogenic factors derived from macrophages or other cell types within the inflammatory infiltrate.
Although the effect of anti-VEGF treatment was not restricted to VEGF-A, dexamethasone is likely to influence many other inflammatory and angiogenic genes that anti-VEGF does not target, or may even upregulate. For instance, significant up-regulation of Insulin-like Growth Factor 1 (IGF-1) and MIP-2 (CXCL2) after bevacizumab treatment has been reported in a corneal alkali burn model (Dratviman-Storobinsky et al., 2009) , while tumor studies have demonstrated the potential of anti-VEGF treatment to induce alternative FGF-2-driven angiogenesis (Alessi et al., 2009) . The difference in neovascularization observed in our model could not be explained by CXCL2 or FGF-2, providing the motivation to examine larger sets of genes, for example using microarray-based techniques, and the detailed composition of the cellular infiltrate.
In summary, we have shown that dexamethasone inhibits both early limbal capillary dilation and early macrophage recruitment in a corneal neovascularization model. These early inhibitory effects, not observed with anti-VEGFA treatment, paralleled the inhibition of corneal neovascular sprouting. Preliminary gene expression analysis indicates that dexamethasone likely acts through the suppression of factors peripheral to several major proinflammatory and proangiogenic pathways. dexamethasone significantly suppressed recruitment of macrophages in comparison to anti-VEGF and controls (P = 0.027). At day 7, the number of macrophages increased in all groups, but remained suppressed in anti-VEGF and dexamethasone groups relative to controls (P = 0.001). Figure 6 . Quantification of corneal neovascularization. (A) At day 2, photographic observation confirmed limbal vessel dilation (white arrows) in anti-VEGF and control groups, but not in dexamethasone-treated corneas. By day 7, almost no vessels were visible in dexamethasone-treated corneas, except for a few thin vessels close to limbus (black arrow). Slight edema (black asterisk) was evident in the suture area. Corneas in anti-VEGF and control groups were densely vascularized to the suture (suture is located 1.5mm from the limbal arcade). (B) Quantification of neovascularization at day 7 revealed that dexamethsone significantly inhibited total vessel length by 95.3% and vessel invasion area by 93.1% compared to controls (P < 0.001). The inhibitory effect of anti-VEGF was significantly weaker than dexamethasone (P < 0.05) with a reduction of vessel length by 14.4% (P > 0.05) and invasion area by 13.8% (P > 0.05) in compared to controls. VEGFA, FGF-2, IL-6, and TNF-α were all significantly suppressed in both treatment groups, with no significant difference between anti-VEGF and dexamethasone. The expression of CXCL2, CCL2, CCL3, and DLL4 were not influenced by treatments. All results represent 3-5 corneas per treatment group. (B) Gene expression at day 7 for VEGFA, FGF-2, IL-6, TNF-α, CXCL2, CCL2, and CCL3 in all groups. In sutured corneas, all cytokines were significantly up-regulated in comparison the native non-sutured cornea (P < 0.001), except for FGF2 which was slightly down-regulated (P > 0.05). Dexamethasone and anti-VEGF down-regulated the expression of VEGFA, IL-6 and CCL2 (P < 0.05) relative to IgG controls. There was no difference in gene expression between dexamethasone and anti-VEGF treatment groups for any of the cytokines (P > 0.05). TNF-α was down-regulated in both dexamethasone and anti-VEGF treated groups relative to IgG controls, but not to a significant level. All results represent 3 corneas per treatment group, except for FGF-2 and CXCL2, where the IgG group consisted of 2 corneas.
